特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

カテーテル関連血流感染症(CRBSI) - 疫学予測 2028年

Catheter-Related Bloodstream Infection (CRBSI) - Epidemiology Forecast to 2028

発行 DelveInsight Business Research LLP 商品コード 909902
出版日 ページ情報 英文 156 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.17円で換算しております。
カテーテル関連血流感染症(CRBSI) - 疫学予測 2028年 Catheter-Related Bloodstream Infection (CRBSI) - Epidemiology Forecast to 2028
出版日: 2020年03月01日 ページ情報: 英文 156 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、スペイン、イタリア、日本)のカテーテル関連血流感染症(CRBSI)の罹患数は、2017年に66万7,753人と推計され、2028年にかけてその数は増加すると予測されています。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、スペイン、イタリア、日本)のカテーテル関連血流感染症(CRBSI)の疫学について調査し、疾患の概要、国別の罹患数および診断数の推移と予測などについてまとめています。

目次

第1章 重要洞察

第2章 カテーテル関連血流感染症(CRBSI):疫学概要

  • 分布状況(実績値)
  • 分布状況(予測値)

第3章 カテーテル関連血流感染症(CRBSI):疾患背景と概要

  • イントロダクション
  • 中心ライン関連血流感染症(CLABSI)とカテーテル関連血流感染症(CRBSI)の違い
  • カテーテル関連血流感染症(CRBSI)の原因
    • 微生物
    • 血管内デバイス
  • カテーテル関連血流感染症(CRBSI)の危険因子
  • カテーテル関連血流感染症(CRBSI)の病因
  • カテーテル関連血流感染症(CRBSI)の診断
  • カテーテル関連血流感染症(CRBSI)の診断ガイドライン

第4章 疫学と患者人口

  • 主な調査結果
  • 主要7カ国のカテーテル関連血流感染症(CRBSI)の総罹患数
  • 主要7カ国のカテーテル関連血流感染症(CRBSI)の診断数
  • 主要7カ国のカテーテル関連血流感染症(CRBSI)の診断数:起炎菌別
  • キーオピニオンリーダーの意見

第5章 米国の疫学

  • 仮定と根拠
  • 総罹患数
  • 総診断数
  • 診断数:起炎菌別

第6章 欧州5カ国の疫学

  • ドイツの疫学
    • 仮定と根拠
    • 総罹患数
    • 総診断数
    • 診断数:起炎菌別
  • フランスの疫学
  • イタリアの疫学
  • スペインの疫学
  • 英国の疫学

第7章 日本の疫学

  • 仮定と根拠
  • 総罹患数
  • 総診断数
  • 診断数:起炎菌別

第8章 付録

  • 調査方法

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

図表

List of Tables

  • Table 1 Terminology: CLABSI or CRBSI
  • Table 2 Various Risk Factors of CRBSIs
  • Table 3 Total Incident Population of CRBSI in the Global Market (2017-2028 )
  • Table 4 Total Diagnosed Incident Population of CRBSI in the Global Market (2017-2028 )
  • Table 5 Total Incident Population of CRBSI in the US (2017-2028)
  • Table 6 Total Diagnosed Incident Population of CRBSI in the US (2017-2028)
  • Table 7 Diagnosed Incidence of CRBSI by Causative Pathogens in the US (2017-2028)
  • Table 8 Total Incident Population of CRBSI in Germany (2017-2028 )
  • Table 9 Total Diagnosed Incident Population of CRBSI in Germany (2017-2028)
  • Table 10 Diagnosed Incidence of CRBSI by Causative Pathogens in Germany (2017-2028)
  • Table 11 Total Incident Population of CRBSI in France (2017-2028)
  • Table 12 Total Diagnosed Incident Population of CRBSI in France (2017-2028)
  • Table 13 Diagnosed Incidence of CRBSI by Causative Pathogens in France (2017-2028)
  • Table 14 Total Incident Population of CRBSI in Italy (2017-2028)
  • Table 15 Total Diagnosed Incident Population of CRBSI in Italy (2017-2028)
  • Table 16 Diagnosed Incidence of CRBSI by Causative Pathogens in Italy (2017-2028 )
  • Table 17 Total Incident Population of CRBSI in Spain (2017-2028)
  • Table 18 Total Diagnosed Incident Population of CRBSI in Spain (2017-2028)
  • Table 19 Diagnosed Incidence of CRBSI by Causative Pathogens in Spain (2017-2028)
  • Table 20 Total Incident Population of CRBSI in the UK (2017-2028)
  • Table 21 Total Diagnosed Incident Population of CRBSI in the UK (2017-2028 )
  • Table 22 Diagnosed Incidence of CRBSI by Causative Pathogens in the UK (2017-2028)
  • Table 23 Total Incident Population of CRBSI in Japan (2017-2028)
  • Table 24 Total Diagnosed Incident Population of CRBSI in Japan (2017-2028)
  • Table 25 Diagnosed Incidence of CRBSI by Causative Pathogens in Japan (2017-2028)
  • Table 26 Total Incident Population of CRBSI in China (2017-2028)
  • Table 27 Total Diagnosed Incident Population of CRBSI in China (2017-2028)
  • Table 28 Diagnosed Incidence of CRBSI by Causative Pathogens in China (2017-2028)
  • Table 29 Total Incident Population of CRBSI in India (2017-2028)
  • Table 30 Total Diagnosed Incident Population of CRBSI in India (2017-2028 )
  • Table 31 Diagnosed Incidence of CRBSI by Causative Pathogens in India (2017-2028)
  • Table 32 Total Incident Population of CRBSI in Taiwan (2017-2028)
  • Table 33 Total Diagnosed Incident Population of CRBSI in Taiwan (2017-2028)
  • Table 34 Diagnosed Incidence of CRBSI by Causative Pathogens in Taiwan (2017-2028)
  • Table 35 Total Incident Population of CRBSI in South Korea (2017-2028)
  • Table 36 Total Diagnosed Incident Population of CRBSI in South Korea (2017-2028)
  • Table 37 Diagnosed Incidence of CRBSI by Causative Pathogens in South Korea (2017-2028)
  • Table 38 Total Incident Population of CRBSI in Australia (2017-2028)
  • Table 39 Total Diagnosed Incident Population of CRBSI in Australia (2017-2028)
  • Table 40 Diagnosed Incidence of CRBSI by Causative Pathogens in Australia (2017-2028)
  • Table 41 Total Incident Population of CRBSI in Argentina (2017-2028)
  • Table 42 Total Diagnosed Incident Population of CRBSI in Argentina (2017-2028)
  • Table 43 Diagnosed Incidence of CRBSI by Causative Pathogens in Argentina (2017-2028)
  • Table 44 Total Incident Population of CRBSI in Brazil (2017-2028)
  • Table 45 Total Diagnosed Incident Population of CRBSI in Brazil (2017-2028)
  • Table 46 Diagnosed Incidence of CRBSI by Causative Pathogens in Brazil (2017-2028)
  • Table 47 Total Incident Population of CRBSI in Mexico (2017-2028)
  • Table 48 Total Diagnosed Incident Population of CRBSI in Mexico (2017-2028)
  • Table 49 Diagnosed Incidence of CRBSI by Causative Pathogens in Mexico (2017-2028)
  • Table 50 Total Incident Population of CRBSI in Colombia (2017-2028)
  • Table 51 Total Diagnosed Incident Population of CRBSI in Colombia (2017-2028)
  • Table 52 Diagnosed Incidence of CRBSI by Causative Pathogens in Colombia (2017-2028)
  • Table 53 Total Incident Population of CRBSI in Saudi Arabia (2017-2028)
  • Table 54 Total Diagnosed Incident Population of CRBSI in Saudi Arabia (2017-2028)
  • Table 55 Diagnosed Incidence of CRBSI by Causative Pathogens in Saudi Arabia (2017-2028)
  • Table 56 Total Incident Population of CRBSI in the United Arab Emirates (2017-2028)
  • Table 57 Total Diagnosed Incident Population of CRBSI in the United Arab Emirates (2017-2028)
  • Table 58 Diagnosed Incidence of CRBSI by Causative Pathogens in the United Arab Emirates (2017-2028)
  • Table 59 Total Incident Population of CRBSI in Russia (2017-2028)
  • Table 60 Total Diagnosed Incident Population of CRBSI in Russia (2017-2028)
  • Table 61 Diagnosed Incidence of CRBSI by Causative Pathogens in Russia (2017-2028)

List of Figures

  • Figure 1 Types of Central Venous and Arterial Catheter and their sites of insertion
  • Figure 2 Important pathogenic determinants of catheter-related Infection
  • Figure 3 Potential sources of infection of a percutaneous intravascular device
  • Figure 4 Total Incident Population of CRBSI in the Global Market (2017-2028 )
  • Figure 5 Total Diagnosed Incident Population of CRBSI in the Global Market (2017-2028 )
  • Figure 6 Total Incident Population of CRBSI in the US (2017-2028)
  • Figure 7 Total Diagnosed Incident Population of CRBSI in the US (2017-2028)
  • Figure 8 Diagnosed Incidence of CRBSI by Causative Pathogens in the US (2017-2028)
  • Figure 9 Total Incident Population of CRBSI in Germany (2017-2028)
  • Figure 10 Total Diagnosed Incident Population of CRBSI in Germany (2017-2028)
  • Figure 11 Diagnosed Incidence of CRBSI by Causative Pathogens in Germany (2017-2028)
  • Figure 12 Total Incident Population of CRBSI in France (2017-2028)
  • Figure 13 Total Diagnosed Incident Population of CRBSI in France (2017-2028)
  • Figure 14 Diagnosed Incidence of CRBSI by Causative Pathogens in France (2017-2028)
  • Figure 15 Total Incident Population of CRBSI in Italy (2017-2028)
  • Figure 16 Total Diagnosed Incident Population of CRBSI in Italy (2017-2028)
  • Figure 17 Diagnosed Incidence of CRBSI by Causative Pathogens in Italy (2017-2028)
  • Figure 18 Total Incident Population of CRBSI in Spain (2017-2028)
  • Figure 19 Total Diagnosed Incident Population of CRBSI in Spain (2017-2028)
  • Figure 20 Diagnosed Incidence of CRBSI by Causative Pathogens in Spain (2017-2028)
  • Figure 21 Total Incident Population of CRBSI in the United Kingdom (2017-2028)
  • Figure 22 Total Diagnosed Incident Population of CRBSI in the United Kingdom (2017-2028 )
  • Figure 23 Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom (2017-2028)
  • Figure 24 Total Incident Population of CRBSI in Japan (2017-2028)
  • Figure 25 Total Diagnosed Incident Population of CRBSI in Japan (2017-2028)
  • Figure 26 Diagnosed Incidence of CRBSI by Causative Pathogens in Japan (2017-2028)
  • Figure 27 Total Incident Population of CRBSI in China (2017-2028)
  • Figure 28 Total Diagnosed Incident Population of CRBSI in China (2017-2028)
  • Figure 29 Diagnosed Incidence of CRBSI by Causative Pathogens in China (2017-2028)
  • Figure 30 Total Incident Population of CRBSI in India (2017-2028)
  • Figure 31 Total Diagnosed Incident Population of CRBSI in India (2017-2028 )
  • Figure 32 Diagnosed Incidence of CRBSI by Causative Pathogens in India (2017-2028 )
  • Figure 33 Total Incident Population of CRBSI in Taiwan (2017-2028)
  • Figure 34 Total Diagnosed Incident Population of CRBSI in Taiwan (2017-2028)
  • Figure 35 Diagnosed Incidence of CRBSI by Causative Pathogens in Taiwan (2017-2028)
  • Figure 36 Total Incident Population of CRBSI in South Korea (2017-2028)
  • Figure 37 Total Diagnosed Incident Population of CRBSI in South Korea (2017-2028)
  • Figure 38 Diagnosed Incidence of CRBSI by Causative Pathogens in South Korea (2017-2028)
  • Figure 39 Total Incident Population of CRBSI in Australia (2017-2028)
  • Figure 40 Total Diagnosed Incident Population of CRBSI in Australia (2017-2028)
  • Figure 41 Diagnosed Incidence of CRBSI by Causative Pathogens in Australia (2017-2028)
  • Figure 42 Total Incident Population of CRBSI in Argentina (2017-2028)
  • Figure 43 Total Diagnosed Incident Population of CRBSI in Argentina (2017-2028)
  • Figure 44 Diagnosed Incidence of CRBSI by Causative Pathogens in Argentina (2017-2028)
  • Figure 45 Total Incident Population of CRBSI in Brazil (2017-2028)
  • Figure 46 Total Diagnosed Incident Population of CRBSI in Brazil (2017-2028)
  • Figure 47 Diagnosed Incidence of CRBSI by Causative Pathogens in Brazil (2017-2028)
  • Figure 48 Total Incident Population of CRBSI in Mexico (2017-2028)
  • Figure 49 Total Diagnosed Incident Population of CRBSI in Mexico (2017-2028)
  • Figure 50 Diagnosed Incidence of CRBSI by Causative Pathogens in Mexico (2017-2028)
  • Figure 51 Total Incident Population of CRBSI in Colombia (2017-2028)
  • Figure 52 Total Diagnosed Incident Population of CRBSI in Colombia (2017-2028)
  • Figure 53 Diagnosed Incidence of CRBSI by Causative Pathogens in Colombia (2017-2028)
  • Figure 54 Total Incident Population of CRBSI in Saudi Arabia (2017-2028)
  • Figure 55 Total Diagnosed Incident Population of CRBSI in Saudi Arabia (2017-2028)
  • Figure 56 Diagnosed Incidence of CRBSI by Causative Pathogens in Saudi Arabia (2017-2028)
  • Figure 57 Total Incident Population of CRBSI in the United Arab Emirates (2017-2028)
  • Figure 58 Total Diagnosed Incident Population of CRBSI in the United Arab Emirates (2017-2028)
  • Figure 59 Diagnosed Incidence of CRBSI by Causative Pathogens in the United Arab Emirates (2017-2028)
  • Figure 60 Total Incident Population of CRBSI in Russia (2017-2028)
  • Figure 61 Total Diagnosed Incident Population of CRBSI in Russia (2017-2028 )
  • Figure 62 Diagnosed Incidence of CRBSI by Causative Pathogens in Russia (2017-2028)
目次
Product Code: DIEI0513

Overview

DelveInsight's 'Catheter-Related Bloodstream Infection (CRBSI) - Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical and forecasted catheter-related bloodstream infection epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, APAC (China, India, Taiwan, South Korea, and Australia), LATAM (Brazil, Mexico, Argentina, and Colombia), Middle East (Saudi Arabia and the United Arab Emirates), and Russia.

Catheter-Related Bloodstream Infection Understanding

Catheter-related bloodstream infection (CRBSI) is defined as the presence of bacteremia originating from an intravascular (I.V.) Catheters (Intravascular catheters are indispensable in modern-day medical practice, particularly in intensive care units (ICUs)). CRBSI refers to bloodstream infection attributed to an intravascular catheter by quantitative culture of the catheter tip or by differences in growth between catheter and peripheral venipuncture blood culture specimens. It is also known as catheter-related sepsis. It is also the most common cause of nosocomial bacteremia.

Catheter-Related Bloodstream Infection Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of CRBSI, Total Diagnosed Incident Population of CRBSI, and Diagnosed Incidence of CRBSI by Causative Pathogens scenario of catheter-related bloodstream infection in the global market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), Japan, APAC (China, India, Taiwan, South Korea, and Australia), LATAM (Brazil, Mexico, Argentina, and Colombia), Middle East (Saudi Arabia and the United Arab Emirates), and Russia from 2017 to 2028.

Catheter-Related Bloodstream Infection Detailed Epidemiology Segmentation

As per DelveInsight's analysis, the total incident population of catheter-related bloodstream infection in the global market was found to be 4,114,882 in 2017 and the diagnosed incident population of catheter-related bloodstream infection in the global market was observed to be 3,920,865 in 2017. The estimates show a higher incidence of catheter-related bloodstream infections in India with 1,722,280 cases in 2017.

According to DelveInsight's assessment, it has been observed among the North American countries, the United States had the highest incident population of catheter-related bloodstream infection with 328,107 cases in 2017. The total incident population of catheter-related bloodstream infection in the APAC region was found to be 3,105,930 cases in 2017, and India accounted for the highest number of cases among all the APAC countries. Among the LATAM region, Brazil accounted for the highest incidence of catheter-related bloodstream infection with 163,405 cases in 2017. Whereas, the least number of cases was contributed by Colombia. In the MENA region, Saudi Arabia shows a higher incidence of catheter-related bloodstream infection with 28,118 cases in 2017.

The estimates show that gram-positive bacteria are implicated in 65-70% of the cases of catheter-related bloodstream infection, whereas gram-negative bacteria account for 30-35% of the cases of catheter-related bloodstream infection in the US, EU5, Japan, India, South Korea, Argentina, and Mexico. Whereas, in countries like China, Taiwan, Australia, Brazil, Colombia, Saudi Arabia, UAE, and Russia, the incidence of gram-negative bacteria is higher as compared to gram-positive bacteria.

Scope of the Report

  • The report covers the descriptive overview of catheter-related bloodstream infection, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • The report provides insight into the global historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), Japan, APAC (China, India, Taiwan, South Korea, and Australia), LATAM (Brazil, Mexico, Argentina, and Colombia), Middle East (Saudi Arabia and the United Arab Emirates), and Russia.
  • The report helps to recognize the growth opportunities in the global market with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology at the global level by Total Incident Population of Catheter-Related Bloodstream Infection, Total Diagnosed Incident Population of Catheter-Related Bloodstream Infection, and Diagnosed Incidence of Catheter-Related Bloodstream Infection by Causative Pathogens.

Report Highlights

  • Nine-Year Forecast of Catheter-Related Bloodstream Infection
  • Global Coverage
  • Total Incident Population of Catheter-Related Bloodstream Infection
  • Total Diagnosed Incident Population of Catheter-Related Bloodstream Infection
  • Diagnosed Incidence of Catheter-Related Bloodstream Infection by Causative Pathogens

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and incidence by the causative pathogen. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What is the disease risk, burden of catheter-related bloodstream infection?
  • What is the historical catheter-related bloodstream infection patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), Japan, APAC (China, India, Taiwan, South Korea, and Australia), LATAM (Brazil, Mexico, Argentina, and Colombia), Middle East (Saudi Arabia and the United Arab Emirates), and Russia?
  • What would be the forecasted patient pool of catheter-related bloodstream infection at the global level?
  • What will be the growth opportunities across the globe with respect to the patient population pertaining to catheter-related bloodstream infection?
  • Out of the above-mentioned countries, which country would have the highest Incident population of catheter-related bloodstream infection during the forecast period (2020-2028)?
  • At what CAGR the population is expected to grow across the globe during the forecast period (2020-2028)?

Reasons to buy

The catheter-related bloodstream infection report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global catheter-related bloodstream infection.
  • Quantify patient populations in the global catheter-related bloodstream infection market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the causative pathogen that presents the best opportunities for catheter-related bloodstream infection therapeutics in each of the markets covered.
  • The catheter-related bloodstream infection epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The catheter-related bloodstream infection epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the nine-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
  • APAC (China, India, Taiwan, South Korea, and Australia)
  • LATAM (Brazil, Mexico, Argentina, and Colombia)
  • Middle East (Saudi Arabia and the United Arab Emirates)
  • Russia

Study Period: 2017-2028

Table of Contents

1. Key Insights

2. Catheter-Related Blood Stream Infection (CRBSI): Epidemiology Overview at a Glance

  • 2.1. Total Incident cases of CRBSI in 2017 and 2028

3. Catheter-Related Bloodstream Infection (CRBSI): Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Difference between CLABSI and CRBSI
  • 3.3. Causes of Catheter-Related Bloodstream Infection (CRBSI)
    • 3.3.1. Micro-organisms
    • 3.3.2. Intravascular Devices
  • 3.4. Risk Factor Associated with Catheter-Related Bloodstream Infection (CRBSI)
  • 3.5. Pathogenesis of Catheter-Related Bloodstream Infection (CRBSI)
  • 3.6. Diagnosis of Catheter-Related Bloodstream Infection (CRBSI)
  • 3.7. Diagnosis Guidelines Catheter-Related Bloodstream Infection (CRBSI)
    • 3.7.1. Infectious Diseases Society of America (IDSA) Guidelines for CRBSI
    • 3.7.2. Spanish Society of Infectious Diseases and Clinical Microbiology and (SEIMC) and the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC)
    • 3.7.3. British Intestinal Failure Alliance (BIFA)
    • 3.7.4. European Renal Best Practice (ERBP) Recommendations for Diagnosis of CRBSIs

4. Epidemiology and Patient Population

    • 4.1.1. Key Findings
    • 4.1.2. Total Incident Population of CRBSI in the Global Market
    • 4.1.3. Total Diagnosed Incident Population of CRBSI in the Global Market
    • 4.1.4. Some KOL Insights

5. United States Epidemiology

  • 5.1. Assumptions and Rationale
  • 5.2. Total Incident Population of CRBSI in the United States
  • 5.3. Total Diagnosed Incident Population of CRBSI in the United States
  • 5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United States

6. EU5 Epidemiology

  • 6.1. Germany Epidemiology
    • 6.1.1. Assumptions and Rationale
    • 6.1.2. Total Incident Population of CRBSI in Germany
    • 6.1.3. Total Diagnosed Incident Population of CRBSI in Germany
    • 6.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Germany
  • 6.2. France Epidemiology
    • 6.2.1. Assumptions and rationale
    • 6.2.2. Total Incident Population of CRBSI in France
    • 6.2.3. Total Diagnosed Incident Population of CRBSI in France
    • 6.2.4. Diagnosed Incidence of CRBSI by Causative Pathogens in France
  • 6.3. Italy Epidemiology
    • 6.3.1. Assumptions and Rationale
    • 6.3.2. Total Incident Population of CRBSI in Italy
    • 6.3.3. Total Diagnosed Incident Population of CRBSI in Italy
    • 6.3.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Italy
  • 6.4. Spain Epidemiology
    • 6.4.1. Assumptions and Rationale
    • 6.4.2. Total Incident Population of CRBSI in Spain
    • 6.4.3. Total Diagnosed Incident Population of CRBSI in Spain
    • 6.4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Spain
  • 6.5. United Kingdom Epidemiology
    • 6.5.1. Assumptions and Rationale
    • 6.5.2. Total Incident Population of CRBSI in the United Kingdom
    • 6.5.3. Total Diagnosed Incident Population of CRBSI in the United Kingdom
    • 6.5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom

7. APAC Epidemiology

  • 7.1. Japan Epidemiology
    • 7.1.1. Assumptions and Rationale
    • 7.1.2. Total Incident Population of CRBSI in Japan
    • 7.1.3. Total Diagnosed Incident Population of CRBSI in Japan
    • 7.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Japan
  • 7.2. China Epidemiology
    • 7.2.1. Assumptions and Rationale
    • 7.2.2. Total Incident Population of CRBSI in China
    • 7.2.3. Total Diagnosed Incident Population of CRBSI in China
    • 7.2.4. Diagnosed Incidence of CRBSI by Causative Pathogens in China
  • 7.3. India Epidemiology
    • 7.3.1. Assumptions and Rationale
    • 7.3.2. Total Incident Population of CRBSI in India
    • 7.3.3. Total Diagnosed Incident Population of CRBSI in India
    • 7.3.4. Diagnosed Incidence of CRBSI by Causative Pathogens in India
  • 7.4. Taiwan Epidemiology
    • 7.4.1. Assumptions and Rationale
    • 7.4.2. Total Incident Population of CRBSI in Taiwan
    • 7.4.3. Total Diagnosed Incident Population of CRBSI in Taiwan
    • 7.4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Taiwan
  • 7.5. South Korea Epidemiology
    • 7.5.1. Assumptions and Rationale
    • 7.5.2. Total Incident Population of CRBSI in South Korea
    • 7.5.3. Total Diagnosed Incident Population of CRBSI in South Korea
    • 7.5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in South Korea
  • 7.6. Australia Epidemiology
    • 7.6.1. Assumptions and Rationale
    • 7.6.2. Total Incident Population of CRBSI in Australia
    • 7.6.3. Total Diagnosed Incident Population of CRBSI in Australia
    • 7.6.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Australia

8. LATAM Epidemiology

  • 8.1. Argentina Epidemiology
    • 8.1.1. Assumptions and Rationale
    • 8.1.2. Total Incident Population of CRBSI in Argentina
    • 8.1.3. Total Diagnosed Incident Population of CRBSI in Argentina
    • 8.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Argentina
  • 8.2. Brazil Epidemiology
    • 8.2.1. Assumptions and Rationale
    • 8.2.2. Total Incident Population of CRBSI in Brazil
    • 8.2.3. Total Diagnosed Incident Population of CRBSI in Brazil
    • 8.2.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Brazil
  • 8.3. Mexico Epidemiology
    • 8.3.1. Assumptions and Rationale
    • 8.3.2. Total Incident Population of CRBSI in Mexico
    • 8.3.3. Total Diagnosed Incident Population of CRBSI in Mexico
    • 8.3.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Mexico
  • 8.4. Colombia Epidemiology
    • 8.4.1. Assumptions and Rationale
    • 8.4.2. Total Incident Population of CRBSI in Colombia
    • 8.4.3. Total Diagnosed Incident Population of CRBSI in Colombia
    • 8.4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Colombia

9. Middle East Epidemiology

  • 9.1. Saudi Arabia Epidemiology
    • 9.1.1. Assumptions and Rationale
    • 9.1.2. Total Incident Population of CRBSI in Saudi Arabia
    • 9.1.3. Total Diagnosed Incident Population of CRBSI in Saudi Arabia
    • 9.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Saudi Arabia
  • 9.2. United Arab Emirates Epidemiology
    • 9.2.1. Assumptions and Rationale
    • 9.2.2. Total Incident Population of CRBSI in the United Arab Emirates
    • 9.2.3. Total Diagnosed Incident Population of CRBSI in the United Arab Emirates
    • 9.2.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United Arab Emirates

10. Russia Epidemiology

    • 10.1.1. Assumptions and Rationale
    • 10.1.2. Total Incident Population of CRBSI in Russia
    • 10.1.3. Total Diagnosed Incident Population of CRBSI in Russia
    • 10.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Russia

11. Appendix

  • 11.1. Report Methodology

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight